Highest-materiality recent filing
DaVita Q2 2026 EPS $4.02, revenue $3.55B; net income up 34% sequentially
Consolidated revenue $3.554B; operating income $579M; diluted EPS $4.02.
DaVita adds $500M senior secured term loan B facility via Ninth Amendment
Incremental Tranche B-2 Term Loans of $500M added to existing credit agreement; maturity May 2031.
DaVita Q1 2026 adj EPS $2.87 vs $2.00 YoY; revenue $3.416B, repurchased 3M shares
GAAP and adjusted diluted EPS $2.87, up 44% YoY from $2.00; down sequentially from $3.40 in Q4 2025.
DaVita Q4 adj. EPS $3.40 vs $2.51 Q3; full-year net income down YoY
Q4 2025 revenue $3.620B, operating income $561M, adj. operating income $586M.
DaVita board authorizes additional $2 billion share repurchase program
Board authorized $2,000,000,000 in additional repurchasing authority under existing share repurchase program.
DaVita Q2 2025: EPS $2.58 ($2.95 adj.); revenue $3.38B; $1B notes issued
Diluted EPS $2.58 ($2.95 adjusted); net income $199M vs Q1 $163M.
DaVita closes $1.0B offering of 6.750% Senior Notes due 2033
Issued $1.0B aggregate principal of 6.750% senior notes maturing July 15, 2033.
DaVita announces private offering of $750M Senior Notes due 2033
$750M aggregate principal amount of 2033 Senior Notes offered in private placement.
DaVita upsizes and prices $1B of 6.750% Senior Notes due 2033
Offering increased from $750M to $1B aggregate principal; notes priced at 100.000% with 6.750% coupon.
DaVita Q1 2025: revenue $3.22B, EPS $2.00, net income $163M down 32% YoY
Consolidated revenues $3.224B; operating income $439M.
DaVita reports ransomware incident on April 12; operations impacted, patient care continues
Ransomware encrypted certain network elements; DaVita isolated impacted systems and activated response protocols.
DaVita Q4 adjusted EPS $2.24, revenue $3.295B; full year EPS $10.73
Q4 2024 revenue $3.295B; operating income $565M; diluted EPS $3.09 (adjusted $2.24).
DaVita Q3 2024: revenue $3.264B, op income $535M, EPS $2.50, adj EPS $2.59
Consolidated revenue $3.264B; operating income $535M; net income $215M ($2.50 diluted EPS).
DaVita appoints David P. Maughan as COO, Kidney Care; Staffieri becomes COO Emeritus
David P. Maughan appointed COO, DaVita Kidney Care, effective September 15, 2024, succeeding Michael D. Staffieri.
DaVita board approves $2B increase to share repurchase program
Board added $2B in repurchase authority; no expiration date, no obligation to repurchase.
DaVita launches $1.0B senior notes due 2032; proceeds to repay Term Loan B-1 and revolver
$1.0B aggregate principal of Senior Notes due 2032 in a private offering under Rule 144A/Reg S.
DaVita Q2 2024 EPS $2.50, revenue $3.187B; raises adjusted EPS to $2.59
Net income $223M, diluted EPS $2.50; adjusted EPS $2.59 on revenue of $3.187B.
DaVita extends $1.64B term loan maturity to 2031, adds $658M incremental term loans
Extended $1,640,250,847 of existing secured term loans from August 2026 to May 2031.
DaVita Q1 2024 net income $240M, EPS $2.65; revenue $3.07B
Revenue $3.071B; operating income $484M; adjusted operating income $463M.
DaVita enters share repurchase agreement with Berkshire Hathaway to cap ownership at 45%
Agreement requires DaVita to repurchase shares from Berkshire quarterly if ownership exceeds 45% of outstanding.
DaVita Q4 revenue $3.15B, adj EPS $1.87; FY adj EPS $8.47, cash flow $2.06B
Q4 2023 consolidated revenue $3.146B; FY 2023 revenue $12.140B.
DaVita Q3 2023 adjusted EPS $2.85, revenue $3.1B, operating cash flow $661M
GAAP diluted EPS $2.62; adjusted diluted EPS $2.85, up from $2.08 in Q2 2023.
DaVita reports Q2 2023 revenue of $3.0B; diluted EPS $1.91, adjusted EPS $2.08
Consolidated revenue $3.0B; operating income $405M; adjusted operating income $432M.
DaVita Q4 2022: revenue $2.917B, adj. EPS $1.11; full-year adj. EPS $6.60
Q4 2022 revenue $2.917B; full-year revenue $11.610B.
DaVita Q3 EPS $1.13 vs $2.30 in prior quarter; cites COVID volume drag and labor pressure
Revenue $2.949B; diluted EPS $1.13, adjusted diluted EPS $1.45.
DaVita Q2 2022 EPS $2.30, revenue $2.93B; six-month net income down 27% YoY
Q2 2022 revenue $2.927B, operating income $433M, diluted EPS $2.30 (vs Q1 2022 EPS $1.61).
DaVita and Medtronic form joint venture to create independent kidney-care device company
Equal equity stakes; Medtronic contributes Renal Care Solutions; DaVita pays $75M cash and $25M other assets.
DaVita Q1 2022 EPS $1.61, down 10% from prior quarter; revenue $2.818B
Diluted EPS of $1.61 vs $1.79 in Q4 2021 and $2.09 in Q1 2021; adjusted EPS $1.61.
DaVita Q4 2021 adjusted EPS $2.02 (+21% YoY); full-year revenue $11.6B
Q4 diluted EPS from cont. ops $1.79 (+7.2% YoY); adjusted diluted EPS $2.02 (+21.0% YoY).
DaVita restates standstill with Berkshire Hathaway; caps additional purchases at 25% ownership
Berkshire agrees not to buy additional DaVita shares if beneficial ownership exceeds 25% of outstanding common stock.
DaVita Q3 2021 EPS $2.36 (+84% YoY); revenue $2.938B; repurchased 2.7M shares
Diluted EPS from continuing ops $2.36 vs $1.28 prior year; adjusted EPS $2.36 vs $1.80.
David P. Maughan, Senior Vice President of the Company, has been appointed Chief Operating Officer, DaVita Kidney Care, effective September 15, 2024
Mr. Maughan will replace Michael D. Staffieri, who will transition to the role of Chief Operating Officer Emeritus, as of the Effective Date.
appointing Dennis W. Pullin as a member of the Board, in each case effective as of April 10, 2024.
when Mr. Winstel steps down from the role, no later than September 5, 2023.
On July 12, 2023, the Board of Directors (the "Board") of DaVita Inc. (the "Company") adopted resolutions expanding the size of the Board from nine to ten members and appointing Wendy L. Schoppert as a member of the Board, in each case effective as of July 14, 2023.
On March 15, 2023, John Winstel, Chief Accounting Officer of DaVita Inc. (the “Company”) notified the Company of his decision to step down from his position, with an expected transition period to end no later than September 5, 2023 (the “Effective Date”).
appointed Adam H. Schechter as a member of the Board, in each case effective as of September 20, 2022.
appointed Jason M. Hollar as a member of the Board, in each case effective as of May 6, 2022.
appointed Gregory J. Moore, M.D., Ph.D. as a member of the Board, to fill the newly created vacancy on the Board, in each case effective as of September 9, 2021.
Max materiality 0.80 · Median 0.65 · Most common event earnings